Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer

Sun Jin Sym MD, Heung Moon Chang PhD, Min-Hee Ryu PhD, Jae-Lyun Lee PhD, Tae Won Kim PhD, Jeong Hwan Yook PhD, Sung Tae Oh PhD, Byung Sik Kim PhD, Yoon-Koo Kang PhD
Gastrointestinal Oncology
Volume 17, Issue 4 / April , 2009

View full article HTML | View full article PDF | Download Citation

Abstract

Background

This phase II study was conducted to evaluate the efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and capecitabine (DXP) in patients with unresectable locally advanced and/or intra-abdominal metastatic gastric cancers.

Methods

Patients with advanced gastric cancer (AGC), clinically unresectable because of local invasion or limited intra-abdominal metastasis in para-aortic lymph nodes and/or the peritoneum based on multidetector row computed tomography, were enrolled. DXP consisted of docetaxel 60 mg/m² i.v. and cisplatin 60 mg/m² i.v. on day 1, and capecitabine 937.5 mg/m² twice daily p.o. on days 1–14 every 21 days. Surgery was performed after 4–6 cycles of DXP.

Results

Thirty-six (74%) of the 49 patients enrolled underwent surgery, and 31 (63%) had an R0 resection. R0 resection was possible in 15 of 21 patients (71%) with unresectable locally advanced lesions, 12 of 17 patients (70%) with para-aortic lymph node metastasis but only 4 of 11 patients (36%) with peritoneal metastasis. Grade 3/4 toxicities included neutropenia (69%), febrile neutropenia (4%) and hand–foot syndrome (8%).

Conclusions

Neoadjuvant DXP may offer a reasonable chance of curative surgery in AGC patients with unresectable locally advanced or para-aortic lymph node metastasis.

Go to Issue Contents